In addition to the role in regulating leukocyte trafficking, chemokines recently have been shown to be involved in cancer growth and metastasis. Chemokine network in tumor neovascularity may be regulated by decoy receptors. Duffy antigen receptor for chemokines (DARC) is a specific decoy receptor binding with the angiogenic CC and CXC chemokines. To investigate the effects of DARC on the tumorigenesis and the metastasis potential of human breast cancer cells, human DARC cDNA was reintroduced into the MDA-MB-231 and MDA-MB-435HM cells which have a high capability of spontaneous pulmonary metastasis. We demonstrated that DARC overexpression induced inhibition of tumorigenesis and/ or metastasis through interfering with the tumor angiogenesis in vivo. This inhibition is associated with decreasing CCL2 protein levels, and MVD and MMP-9 expression in xenograft tumors. In human breast cancer samples, we also demonstrated that low expression of the DARC protein is significantly associated with estrogen receptor (ER) status, MVD, lymph node metastasis, distant metastasis and poor survival. Our results suggest for the first time that DARC is a negative regulator of growth in breast cancer, mainly by sequestration of angiogenic chemokines and subsequent inhibition of tumor neovascularity.
Introduction
Breast cancer is the leading malignancy of woman in western countries and in some big cities in China. The treatment failures are usually associated with distant metastasis of tumor cells. The molecular mechanisms involved in distant metastasis are still largely unknown. To make progress in this area, it is essential to obtain more detailed knowledge of the molecular mechanisms involved in metastasis. Recently, chemokines and their receptors, for example CXCL12 (SDF-1)-CXCR4 biological axis, have been demonstrated to be associated with growth and metastasis of cancer cells (Vicari and Caux, 2002; Balkwill, 2004) , in addition to their role in regulating leukocyte trafficking. Many studies suggest that some chemokines such as CXCL8 (IL-8) and CCL2 (MCP-1, MCAF, JE) accelerate tumor growth and metastasis through their enhancement of angiogenesis. However, the precise regulatory mechanism has not been identified. We speculate that intratumor chemokine network consisting of angiogenic chemokine and angiostatic chemokine may be at least partly regulated by chemokine decoy receptors, such as DARC, D6 and CCX-CKR.
Duffy antigen, also called Duffy antigen receptor for chemokines (DARC) is a typical decoy receptor that binds with angiogenic ELR þ (glutamine-leucinearginine motif in N-terminus) CXC chemokines, as well as some CC chemokines (Neote et al., 1993 (Neote et al., , 1994 , but not with ELR À CXC chemokines and C chemokine (Szabo et al., 1995) . DARC ligands with high affinity include CXCL1 (GROa), CXCL2 (GROb), CXCL3 (GROg), CXCL4 (PF4), CXCL5 (ENA-78), CXCL7 (NAP-2), CXCL8 (IL-8), CCL2 (MCP-1, MCAF, JE), CCL5 (RANTES), CCL7 (MCP-3), CCL11 (Eotaxin), CCL13 (MCP-4), CCL14 (HCC-1) and CCL17 (TARC), etc (Comerford and Nibbs, 2005) . The chemokine regulation by DARC may be indispensable as indicated by its' broad distribution on endothelial cells (ECs), even in Duffy negative individuals who lack the erythrocyte receptor (Peiper et al., 1995) . Immunoelectronic microscopy studies have demonstrated that chemokines injected into the skin in vivo or ex vivo were internalized by ECs and detected in intracellular transport caveloae compartment, later shown to contain Duffy antigen (Chaudhuri et al., 1997; Middleton et al., 1997) . Du et al. (2002) observed that Duffy antigen downmodulates the angiogenic effect of CXC chemokines in transgenic mice. In these studies, Duffy antigen and CXCR2 (the receptor mediating the angiogenic effects) are both expressed by the ECs, and therefore, the internalization of pro-angiogenic CXC chemokines by DARC sequesters them away from the responsible signaling receptor, thus DARC displays a true 'decoy' function (Nibbs et al., 2003) . Lentsch (2002) indicated that the expression of DARC may be associated with the incidence of prostate cancer according to an epidemiological data. Approximately 70% of African Americans lack erythrocyte expression of DARC. The Duffy-negative blood phenotype comes from a single T to C promoter mutation (Tournamille et al., 1995; Castilho et al., 2004; Chaudhuri et al., 2004) . African American men have a 60% greater incidence of prostate cancer and a twofold higher mortality rate than the Caucasian men. Therefore, it is presumed that the lack of DARC expression on erythrocytes may represent an epigenetic factor that predisposes the African American men to a greater incidence and mortality of prostate cancer. Addison et al. (2004) had recently studied the effects of DARC on lung cancer cells and showed that DARC induced larger tumor, with reduced cellularity, significant necrosis, lower MVD and decreased metastasis. To further investigate the effects of DARC on the tumorigenesis and the metastatic potential of human breast cancer cells, human Duffy antigen receptor for chemokines (DARC) cDNA was reintroduced into the MDA-MB-435HM and MDA-MB-231 cells by stable transfection. We demonstrate in this report that DARC inhibits both tumorigenesis and/or metastatic potential and this is associated with the clearance of angiogenic chemokines, inhibition of neovacularity and the downregulation of MMP-9 expression.
Results
In vivo selection and metastasis assay MDA-MB-435HM, generated as described in 'Material and methods' metastasized consistently to the lungs in 4 weeks in 100% of athymic nude mice as compared to less than 30% in wild-type MDA-MB-435.
Expression of DARC in human breast cancer cells DARC expression in human breast cancer cell MDA-MB-435 was determined utilizing reverse transcriptionpolymerase chain reaction (RT-PCR) and Western blot analyses in a panel of MDA-MB-435 cells, including MDA-MB-435, MDA-MB-435LM and MDA-MB-435HM. We found that wild-type MDA-MB-435 cells expressed relative high DARC levels, while MDA-MB-435HM cells had a significant lower DARC expression (Figures 1 and 2 ). In addition, we also investigated the gene expression of DARC on a panel of human breast cancer cell lines including MCF-7, MDA-MB-231, T47D ZR-75-30 cells by RT-PCR method. We found that breast cancer cell lines differentially expressed DARC mRNA and protein. We found that DARC expression levels may correlate with ER status which ER-positive cell lines such as MCF-7, T47D express higher DARC levels, and ER-negative cell lines such as MDA-MB-231 and MDA-MB-435 cells express lower DARC levels (Figure 1 ). This correlation was further confirmed in our breast cancer samples (Po0.05) (Figure 6c ). DARC has no effect on proliferation, invasion and chemokines gene expression but enhance clearance of chemokines on protein level in vitro To investigate whether DARC expression could modulate the proliferation and invasion of MDA-MB-435HM and MDA-MB-231 cells in vitro, we assessed the growth and invasion of DARC and mock-transfected cells. DARC had no effect on the proliferation and invasion of DARC-transfected MDA-MB-435HM and MDA-MB-231 cells when compared to mocktransfected and wild-type cells. In addition, DARC expression had no effect on CXCL8 (CXC chemokine ligand 8, interleukin-8, IL-8), CCL2 (CC chemokine ligand 2, monocyte chemoattractant protein-1, MCP-1), MMPs (matrix metalloproteinase), VEGF (vascular endothelial cell growth factor), bFGF (basic fibroblast growth factor) and CXCR4 (receptor for chemokine SDF-1) mRNA expression (data not shown).
The Duffy antigen receptor for chemokines (DARC) functions as a promiscuous chemokine decoy receptor. Therefore, it is interesting to investigate the influence of high expression of DARC on the secretion of chemokines in this system. There were no significant differences of mRNA expression of CXCL8 and CCL2 in DARC, Mock-transfected and wild-type MDA-MB-435HM and MDA-MB-231 cells (data not shown). However, the CXCL8 and CCL2 levels detected in conditioned media from the cells were markedly reduced in the DARC-tansfected cells as compared to the control cells (Figure 3 ).
DARC inhibited tumorigenesis and metastasis through interfering with the tumor angiogenesis in vivo studies
The growth and progression of breast cancer depends on angiogenesis. It has been demonstrated that angiogenic chemokines play an important role in this process. We speculate that the capture and clearance of angiogenic chemokines might result in retardment of tumor growth and metastasis.
DARC-transfected MDA-MB-435HM and MDA-MB-231 cells grew much slower than mock-transfected or wild-type cells in nude mice (Figure 4a) Figure 4a ) (Po0.01). In addition, there was almost threefold decrease in both the numbers and the sizes of Inhibition of breast cancer growth and metastasis by DARC J Wang et al lung metastases in DARC-transfected MDA-MB-435HM xenografts compared to that in mock-transfected or wild-type MDA-MB-435HM cells (data not shown) (Po0.01). A second clone of DARC-transfected MDA-MB-435HM displayed similar in vivo results. As MDA-MB-231 cells have very low potential of lung metastasis, we did not find any significant difference of lung metastasis between the two groups (data not shown).
We examined the potential mechanisms involved in the inhibition by DARC of tumorigenesis and metastasis in vivo. We determined the expression of a number of potential factors including cyclins, MMPs, decidual protein induced by progesterone (DEPP), tropomyosin 3 (TM3), bFGF, VEGF and CXCR4. DARC-transfected MDA-MB-435HM cells constitutively expressed 80% lower levels of MMP-9 mRNA and 60% lower MMP-9 protein than mock-transfected or wild-type cells (Po0.05) (Figure 4b-d) . We did not find any significant difference in cyclins, MMP2, DEPP, TM3, bFGF, VEGF and CXCR4 mRNA expression among DARCtransfected MDA-MB-435HM cells, mock-transfected and wild-type cells (data not shown).
We also investigated the influence of high expression of DARC on local concentration of target chemokines which may come from human tumor cells or mouse tissue in vivo. We observed a significant decrease in mouse CCL2 (JE) levels in DARC-transfected MDA-MB-435HM xenografts as compared to the mocktransfected and wild-type MDA-MB-435HM xenografts (76.2 and 75.5% decrease) 8 weeks after injection (Po0.01) (Figure 4e ). However, we did not find any significant difference of human CCL2 (MCP-1) and human CXCL8 (IL-8) protein levels among DARC-transfected, Mock-transfected and wild-type MDA-MB-435HM. We did not detect mouse CXCL8 in our in vivo study, since mouse CXCL8 has not to be identified yet.
In almost all of xenografts formed in mammary fat pad, the necrosis was observed, but had no significant difference between DARC-overexpressing animals and control animals (Figure 5a and d) . In addition, no apparent necrosis could be found in the pulmonary metastatic tumors.
To further demonstrate the function of DARC, we examined MVD in DARC-transfected, mock-transfected and wild-type MDA-MB-435HM xenografts by using CD34 staining. As shown in Figure 5 , the MVD of DARC-transfected MDA-MB-435HM tumors was significantly less than mock-transfected and wild-type MDA-MB-435HM xenografts (Po0.01) (Figure 5a and b). Inhibition of breast cancer growth and metastasis by DARC J Wang et al DARC association with the MVD, ER, the lymph node metastasis and survival in human breast cancer patients A group of 75 cases of invasive breast cancer treated surgically were investigated with immunohistochemical analysis. The patient's characteristic is shown in Table 1 . We found that there was a strong negative correlation between DARC expression and lymph node metastasis (Po0.01) (Figure 6a ). In lymph node metastasis group (the tumor size was 3.7971.34 cm), only 48.6% cases were DARC high expression. However, 81.6% cases were DARC high expression in lymph node negative group (the primary tumor size was 1.9270.53 cm). In view of the difference of tumor size between two groups described as above, a further analysis was performed in 40 out of 75 cases. In these 40 cases, tumor size was within 1.5-3.0 cm, and no significant difference was found between lymph node negative group (2.2170.48 cm) and lymph node positive group (2.3970.62 cm). As shown in Table 2 and Figure 6g , in this further subanalysis, a strong negative correlation between DARC expression and lymph node status was also confirmed, similarly as the findings from the total 75 cases. We also demonstrated that there was a strongly negative relationship between MVD and DARC staining (Po0.01) (Figure 6b ). Further more, we confirmed in our breast cancer samples there was a strong negative correlation between DARC expression and ER status (Po0.05) (Figure 6c ). In total 13 cases who had distant metastasis, nine cases (69.2%) were DARC low expressors, four cases (30.8%) were DARC high expressors. When comparing the overall survivals, we demonstrated that the tumors of high DARC expression had better survival whenever in LN positive, LN negative and all group of patients ( Figure 6d , e and f), although the difference in lymph node positive patients was not significant (P ¼ 0.1586).
Discussion
The Duffy antigen receptor for chemokines (DARC) specially functions as a promiscuous chemokine decoy receptor (Neote et al., 1993; Tournamille et al., 2004) . The detection of the angiogenic chemokines internalized intracellularly indicates that DARC had the effect of clearing those chemokines. Our preliminary studies have shown that breast cancer cells express several angiogenic chemokines. We suspect that regulator DARC may also participate angiogenesis in breast cancer. Although some studies had shown that DARC is expressed in several kinds of tumors, including erythroleukemia Inhibition of breast cancer growth and metastasis by DARC J Wang et al , glioblastoma (Desbaillets et al., 1997) and hemangiosarcomas (Tang et al., 1998) , the function of DARC in tumors remains unknown. In order to investigate the effects and the mechanisms of DARC in breast tumor, we established DARC overexpressing MDA-MB-435HM and MDA-MB-231 cell lines by stable transfection. Our results clearly show that DARC overexpression induced inhibited tumorigenesis and metastasis perhaps through interfering with the tumor angiogenesis in vivo studies. Addison et al. (2004) observed that tumors derived DARC-expressing A549 lung cancer cells were significantly larger in size, with reduced cellularity, significant necrosis, lower MVD and decreased metastasis. However, our results from breast tumor xenografts reveal that the overexpression of DARC attenuates tumor growth and metastasis. In almost all of xenografts formed in mammary fat pad, the necrosis was observed, but had no significant difference between DARC-overexpression and control groups. In addition, no apparent necrosis could be found in the pulmonary metastatic tumors. Based on the present limited results from Addison and ours, it may be difficult to well explain the discrepancies about tumor growth and necrosis. This may reflect the diversity of inheritance and biological responsibility in different tumor cell lines, including cell lines from lung and breast tumor. The other possible reason may be in the initial DARC status, because the lung tumor cell lines A549 are DARC deficient ones, whereas breast cancer cell lines MDA-MB-435 can constitutively express DARC at low level.
Angiogenesis is regulated by angiogenic and angiostatic chemokines. For example, most of the CXC chemokines with the presence of the structural/functional motif (Glutamic acid-Leucine-Arginine; ELR motif) including CXCL8, and many CC chemokines including CCL2, are known for their positive functions in the regulation of angiogenesis, which indicates their potential role in the tumorigenesis and the metastasis processes (Neote et al., 1994; Salcedo et al., 2000) . In contrast, CXC chemokines that lack the ELR motif may function as a potent inhibitor of angiogenesis. These findings suggested a functional role of chemokines in regulating the angiogenic potential, supporting the hypothesis that the biological balance between angiogenic and angiostatic chemokines may play an important role in regulating overall angiogenesis. In addition to the role of chemokines in angiogenesis, they may be involved in the process of tumor cell migration, invasion and metastasis. The expression of CCL2 had a significant correlation with the expression of angiogenic factors, tumor progression and microvessel density in 
Inhibition of breast cancer growth and metastasis by DARC
J Wang et al breast carcinoma (Saji et al., 2001) . In human glioma and glioblastoma, CXCL8 is expressed and secreted at high levels, and associated with tumor neovascularity and progression (Brat et al., 2005) . In nude mice xenograft tumor from human prostate cancer PC-3 cells expressing high levels of CXCL8, highly tumorigenic, producing rapidly growing, highly vascularized prostate tumors and with a 100% incidence of lymph node metastasis were observed (Kim et al., 2001) . It has been demonstrated that injection of CXCL8 antibody into tumor-bearing SCID mice whose tumor secretes CXCL8 inhibits the growth of tumor (Strieter et al., 1995) . In general, angiogenic chemokines stimulate intratumor neovascularity directly or in combination with VEGF and bFGF. However, their precise regulatory mechanism is unclear so far. Our preliminary studies revealed that both angiogenic chemokines CXCL8, CCL2 and their decoy receptor Duffy antigen receptor for chemokines (DARC) were simultaneously and constitutionally expressed in some of human breast cancer cell lines, such as MCF-7, MDA-MB-231 and MDA-MB-435, suggesting that a post-translational control of angiogenic chemokines in angiogenesis-dependent solid cancer may exist.
In the present study, we demonstrated that overexpression of DARC in MDA-MB-435HM and MDA-MB-231 cells can significantly inhibit tumorigenesis and lung metastasis in vivo. These inhibitions were associated with downregulation of MMP-9 protein levels and decreasing MVD (microvessel density) in xenograft tumors. Similar results were also observed in MDA-MB-231 cells. However, we did not find any significant difference in the proliferation and invasion potential, comparing the DARC-transfected cells with the mocktranfected cells or wild-type MDA-MB-435HM, which indicating that the enhanced expression of DARC had no remarkable influence on the intracellular signaling pathway associated with the tumor cells proliferation and invasion in vitro. It has been reported that DARC gene modification has no influence in cell growth characteristics in vitro, except for their acquired chemokine-binding capacity in human erythroleukemic cell line K562 (Chaudhuri et al., 1994) as well as in human pulmonary cancer cell A549 (Addison et al., 2004) . DARC gene expression appears to effect in vivo growth and has no effect on in vitro growth. This is to be expected if its major effects are on angiogenesis. In fact, a number of factors can just play a role in vivo rather than in vitro. Interleukin-13 receptor (IL-13R) overexpression profoundly inhibited MDA-MB-231 tumor in athymic nude mice, but no difference in vitro growth was found between the transfected cells and mock cells (Kawakami et al., 2001) . These phenomenon also exist for many chemokines, such as CCL16 (liverexpressed chemokine, LEC) (Giovarelli et al., 2000) and CCL19 (EBI1-ligand chemokine, ELC) (Braun et al., 2000) .
Both CXCL8 and CCL2 gene expression in DARCtransfected cells have no significant change, but their protein levels in conditioned media were markedly reduced, suggesting that DARC-transfected cells have already obtained a high clearance capability for target chemokines. The decreasing of CCL2 protein level but not mRNA expression in the xenograft tumor may also due to the DARC, a powerful chemokine controller in post-translational but not translational stage.
Matrix metalloproteinases play important roles in tumor growth, invasion and metastasis. The activation of monocytes by chemokines leads to the releasing of matrix metalloproteinases. CXCL8 (Inoue et al., 2000) and CCL2 (Saji et al., 2001; Schutyser et al., 2002) were demonstrated to increase the releasing of MMP-9, resulting in the digesting extracellular matrix and allowing for tumor cells invasion. In our study, we demonstrated that MMP-9 protein expression was significantly downregulated in DARC-transfused MDA-MB-435HM xenografts. This may also contributed to the inhibition of tumor growth and metastasis.
In the present study, we also examined the DARC protein expression in 75 cases of human breast cancer samples. We found that there was a strong negative correlation between DARC expression and lymph node metastasis. We also demonstrated that there was a strongly negative relationship between MVD and DARC staining. DARC expression correlated with patient's survival. It is interesting to observe that DARC expression levels strong correlated with ER status both in breast cancer cell lines and breast cancer samples. These clinical results may further confirm our preclinical data which indicates that the overexpression of DARC enhanced tumor cells capacity of clearing the angiogenic Inhibition of breast cancer growth and metastasis by DARC J Wang et al chemokines and inhibited tumorigenesis, angiogenesis and tumor cells metastasis.
In conclusion, our results indicate that DARC plays a negative regulatory role in human breast cancer. Overexpression of DARC protein in breast cancer cells can result in significantly inhibition of tumorigenesis and lung metastasis in vivo. The special anticancer efficiency of DARC may be a result of angiogenic chemokine clearance and consequential insufficient neovascularity. These finding may lead to a new therapeutic strategy against breast cancer and other angiogenesis-dependent solid cancer. Inhibition of breast cancer growth and metastasis by DARC J Wang et al
Materials and methods

Regents and cell lines
Dulbecco's modified Eagle's medium, Ham's F-12 medium (DMEM/F12), and fetal bovine serum (FBS) were obtained from Life Technologies Inc., Iscove's modified Eagle's medium (phenol red-free) were purchased from Biofluids (Rockville, MD, USA). The plasmid pcDNA3.0 containing human DARC FyB cDNA was kindly provided by Dr Christophe Tournamille (Institut National de la Transfusion Sanguine, Paris, France). Human breast cancer cell lines MDA-MB-435 and MDA-MB-231 were obtained from ATCC. Cells were routinely cultured in DMEM/F12 medium supplemented with 10% FBS. The cultures were incubated at 371C in a humidified 5% CO 2 atmosphere.
In vivo screening
In vivo screening was conducted in nude mice. Approximately 1 Â 10 6 MDA-MB-435 cells in 0.1 ml culture medium were injected into the mammary fat pad (MFP) of mice to form subcutaneous tumor. Six weeks later, the animals were killed and autopsied. Lungs were assessed for metastases utilizing histopathological studies (see below). Wild-type MDA-MB-435 breast cancer cells when injected in nude mice, usually develop lung metastases in 60% of nude mice in 6 weeks (Urquidi et al., 2002) . Cells from lung metastasis, were cultured in vitro and expanded. These cells were then reinjected into the MFP again and further expanded. This was repeated for six cycles to generate high lung metastasis of MDA-MB-435 (called MDA-MB-435HM cells) with a high propensity to metastasize to lung. Cells from xenograft tumors which did not develop lung metastasis were cultured in vitro and expanded. These cells were then reinjected into the MFP again and further expanded. This was repeated for six cycles to generate low MDA-MB-435 cells (called MDA-MB-435LM cells) with low lung metastatic potential.
Stable transfections
For stable transfection of DARC cDNA, the MDA-MB-435HM and MDA-MB-231 cells were initially plated at a density of 3 Â 10 5 cells in six-well plate for 24 h before transfection in regular medium. Two mg of the expression plasmid pcDNA3.0 with or without DARC were transfected using the Lipofectamine reagent (Life Technologies Inc., Rockville, MD, USA). After 48 h, medium was replaced and G418 was added to select stable transfectants. G418 sulfate (geneticin)-resistant colonies were selected in medium with G418 and expanded. The DARC-positive colonies were identified by RT-PCR and Western blot.
Expression analysis of DARC transfectants RNA isolation and RT-PCR analysis Total RNA was isolated from DARC, mock-transfected and wild-type cells using Trizol reagent (Life Technologies Inc.) according to the manufacturer's recommendations. One mg of total RNA was converted to cDNA using an avian myeloblastosis virus reverse transcription system (Promega, Madison, WI, USA). 2.5 ml of each RT reaction mixture was applied to 25 ml of PCR mixture, containing 2.5 U AmpliTaq DNA polymerase (Promega), 1.5 mmol/l MgCl 2 , 1Â Taq buffer and 0.2 mmol/l 4 deoxynucleotide triphosphates (dNTPs). The specific primers of DARC and other relevant molecules used in the experiment were the following: 
bp 551C
To compare the mRNA relative expression, the semiquantitative RT-PCR was used in our study. Namely, all of mRNAs of objective molecules were normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. Each reaction condition including annealing temperature and PCR cycle was carefully optimized through pilot experiments, to make sure that the amplification reaction is in linear range. Thirty cycles of PCR were carried out for DARC with the program of 30 s at 941C, 30 s at 601C and 1 min at 721C. A total of 26, 30 and 25 cycles of PCR were carried out for CXCL8, CCL2 and GAPDH (a house-keeping gene), respectively. The PCR products was electrophoresed on 1.5% agarose gel and imaged on an ChemiImage 5500 Imaging System (Alpha Innotech, San Leandro, CA, USA). Densitometry of images was performed using NIH Image version 1.62.
Western blot
Cells were washed twice with ice-cold PBS and scarped into 1 ml of ice-cold NP40 lysis buffer (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% (v/v) NP40, 1 mM EDTA (ethylene diaminetetraacetic acid, editic acid), 50 mM NaF, 5 mM Na PPI, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin and 1 mg/ml pepstatin A). Cells were then sonicated for 5 s at 5 W. Insoluble debris was removed by centrifugation at 1000 g for 15 min. Total proteins (50 mg) were analysed by 10% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). Western blot, using mouse anti-human Fy3 monoclonal antibody against to DARC (MIMA-29, a gift from Dr Marion E Reid, New York Blood Center, USA), was performed according to standard protocols. Blot quantification was done with a Molecular Dynamics Laser Densitometer (Model PSD) and the Image Quant Version 1 software.
Western blot for MMP-9
Western blots were performed as has been described previously. Polyacrylamide gels (15% and 10%) were used to detect matrix metalloprotease-9 (MMP-9) proteins, respectively. The blots were probed with rabbit anti-human MMP-9 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:500, and then incubated with a horseradishperoxidase conjugated goat anti-rabbit IgG antibody (Amersham Pharmacia Biotech) diluted 1:2000. Normalization of protein loading was done with b-actin.
In vivo study with animal experiment Female athymic BALB/c nu/nu mice, 4-6 weeks old, were obtained from Shanghai Institute of Materia Medica, Chinese Academy of Science, and housed in laminar-flow cabinets under specific pathogen-free (SPF) condition. All studies on mice were conducted in accordance with the National Institutes of Health 'Guide for the Care and Use of Laboratory Animals'. The study protocol was approved by Shanghai Medical Experimental Animal Care Committee.
The tumorigenicity and spontaneous metastatic capability of the cell lines were determined by injection into the mammary fat pad (MFP). Cells (1 Â 10 6 ) in 0.1 ml of culture medium were inoculated into the anesthetized mouse. Animals were monitored every 2 days for up to 8 weeks for tumor growth and general health. The rate of primary tumor growth of different cells was determined by plotting the means of two orthogonal diameters of the tumors, measured at 7-day intervals. Animals were killed and autopsied at 4, 6, 8 weeks postinoculation. Metastasis formation was assessed by macroscopic observation of all major organs for secondary tumors and confirmed by histological examination of organs. Tissue samples harvested for histological analysis were either fixed and embedded in paraffin wax or snap-frozen in liquid nitrogen.
Enzyme linked immunosorbent assay analysis
The protein level of human CXCL8 and human CCL2 present in conditioned cell supernatants were determined using a sandwich enzyme linked immunosorbent assay (ELISA) kit (Human IL-8/NAP-1, Human MCP-1/CCL2 immunoassay kit, BioSource International). The OD of the test sample was compared with the standard curve. And the amount of mouse CCL2 (JE) in DARC, mock-transfected and wild-type MDA-MB-435HM xenografts in 4, 6 and 8 weeks were also determined by ELISA kit (Mouse CCL2/JE/MCP-1 DuoSet, R&D Systems Inc., USA). JE concentrations in the supernatants of homogenized xenografts were determined in duplicates according to the instruction booklets supplied by the manufacturers.
Immunohistochemical detection of DARC and CD34
Tumor sections were subjected to immunohistochemical staining for DARC and CD34. Tumor sections were incubated in a 1:50 dilution of mouse anti-human Fy3 monoclonal antibody against to DARC (MIMA-29, a gift from Dr Marion E Reid, New York Blood Center), and 1:200 dilution of mouse anti-human CD34 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) serum or mouse preimmune serum (used on human breast cancer sections), and 1:10 dilution of rat anti-mouse CD34 serum or rat preimmune serum. Primary antibody was detected with biotinylated antibodies followed by incubation with streptavidin-conjugated horseradish peroxidase (SA-HRP) and colorimetric detection with 3,3 0 -diaminobenzidine (DAB). The all of informed consent form (ICF) from the patients have been obtained. This study has been approved by the Institutional Review Board (IRB) of the Cancer Hospital, Fudan University in advance.
Evaluation for immunostaining DARC expressed on the membrane and inside of tumor cells. Sections were evaluated microscopically by two independent investigators, who were blinded to patient outcome, using objectives with Â 10 and Â 40 magnification. Both staining intensity and the percentage of positive cells were determined. For DARC, tumor staining was classified as high expression if at least 25% of the cytoplasmic cells were stained with moderate to high staining intensity, and low expression if staining was weak or less than 25% of the cells stained.
CD34-stained sections were scanned at low magnification ( Â 40) to determine areas with the highest number of microvessels (hot spots). Microvessels whose diameters were less than that of eight red cells were counted at a magnification of Â 200 in two hot spots on each section and microvessel density (MVD) was calculated as the average of the two measurements.
Statistical analysis
Analysis of variance and Student's t-test were used to determine the statistical significance of differences between experimental groups. Shanghai Science and Technology Committee (03J14019,
